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Langerhans cells (LCs) are dendritic epidermal cells 
whose ability to function as accessory/stimulatory cells 
in initiating the immune response is, like that of mac-
rophages, dependent on the expression of class II major 
histocompatibility antigens. In normal human skin ap-
proximately 50% of LCs identified by cell surface T6 
antigenicity also express HLA-DR histocompability de-
terminants. We report here that recombinant DNA-de-
rived human interferon (IFN)-gamma, but not IFN-
alpha2, induces the expression of HLA-DR antigens by 
the population of human epidermal LCs on which such 
antigens normally are not detected. IFN-gamma effec-
tively induced HLA-DR on both neonatal and adult epi-
d ermal LCs and such induction was blocked by neutral-
ization with a murine monoclonal antibody to IFN-
gamma. IFN-gamma induction of LC HLA-DR expres-
sion is inhibited by prostaglandin E2 (PGE2) and is mim-
icked by the presence of fatty acid cyclooxygenase in-
hibitors, known to reduce PGE2 production. These re-
sults suggest that IFN-gamma may play a role in regu-
lating skin-associated immune responses through en-
hanced expression of HLA-DR antigens on LCs and that 
such enhancement may be mediated by alterations in 
arachidonic acid metabolism. 
The major hi stocompat ibility complex encodes for two 
classes of cell surface glycop roteins. In humans these membrane 
proteins are class 1 (HLA-A, B, C) and class II (HLA-DR, DS, 
SB) molecu les [1-3]. In contrast to class I antigens which are 
expressed upon most somatic cel ls except adu lt erythrocytes, 
class II ant igens have a restricted cellular distribution. The 
most extensive ly studied class II antigen, HLA-DR, for exam-
ple, is norma lly expressed only by B cells and accessory cells 
such as monocytes, macrophages, dendritic ce lls, and Laager-
hans cell s (LCs) (4- 7]. HLA-DR molecules are homologous 
structurall y and functiona lly with murine Ia surface glycopro-
teins (8], and are functionally important in that their expres-
sion is required for accessory cells to present nominal antigen 
to helper T cell s and initiate the immune response [9- 13]. 
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HLA-DR molecules are also important as stimulatory antigens 
in triggering mixed lymphocyte reactions [9] and mixed epider-
mal cell- lymphocyte reactions [12,13]. 
Several studies in both the human and murine systems have 
indicated that expression of DR/la antigens upon B cells and 
macrophages can be stimulated by soluble products of activated 
T cells [14- 17] . Specifically, recent studies have identified the 
DR/la inducing lymphokine as interferon (IFN) -gamma, and 
have shown that IFN-gamma produced from the cloned IFN-
gamma gene is capable of such DR/la induction [18- 20]. Both 
IFN-a lpha and IFN-beta appear to be either less effective or 
ineffective as DR/la inducers (21,22]. 
LCs, which are derived from bone marrow precursor cells 
[23] and reside within the epidermis, share many characteristics 
with rnacrophages inducing DR/la expression [6,7) and acces-
sory cell functions [10- 13,24). LCs are the on ly cells in the 
normal human epidermis to express DR-antigen and the cell 
surface antigen T6, a molecule a lso found on 70% of human 
thymocytes [25]. Just as not all macrophages express DR 
antigens, using immunofluorescent microscopic techniques, we 
and others have found that approximately 50% of TG bearing 
LCs do not express detectable levels of DR antigens [26- 28]. 
In this study we report a selective enhancement of HLA-DR 
expression on human epidermal LCs that is effected by expo-
sure to recombinant DNA-derived IFN-gamma, but not to IFN-
aJpha2. 
The intracellular mechanisms responsible for IFN-gamma 
induction of DR/la antigens are unknown, but studies with 
murine macrophages suggest that products of the arachidonic 
acid cascade are involved as prostaglandins of the E series 
(PGE) were reported to inhibit lymphokine-induced Ia expres -
sion [18,29]. Moreover, the cyclooxygenase inhibitor, indo-
methac in, mimicked lymphokine action by inducing macro-
phage la expression by itself (29] . Similarly, we report here 
that PGE2 inhibits the IFN-gamma induced HLA-DR expres -
sion on LCs and further demonstrate that indomethacin and 3 
other cyclooxygenase inhibitors can mimic IFN -gamma action 
by increasing HLA-DR expression on LCs. 
MATERIALS AND METHODS 
Interferons an.d Anti-Interferons 
Human recombinant IFN-alpha, (6.6 x 107 units/ml) from Esche-
richia coli was kindly supplied by Schering Corporation, Kenilworth , 
New Jersey. Human recombinant E. coli-derived IFN-gamma (1.0 x 
107 units/ml) and murine monoclonal antibody (lgG!) to human IFN-
gamma (5 x 104 neutralizing units/ml) were kindly supplied by Genen-
tech, Inc., South San Francisco, California. 
Chemicals 
PGE,, t.hromboxane B2 (TXB2), indomethacin , nordihydroguaiaretic 
acid (NDGA), and imidazole were obtained from Sigma Chemical, St. 
Loui s, Missouri. Benoxaprofen and 5,8,11,14-eicosatetraynoic acid 
(ETYA) were obtained from Eli Lilly, Inc. , Indianapolis, Indiana and 
Hoffm ann-LaRoche, Inc., Nutley, New Jersey. PGE2, TXB2, and in-
domethacin were dissolved in absolute ethanol and diluted in RPMI-
10% heat-inactivated fetal calf serum (.6FCS) to the fi nal tested 
concentrations. At the dilutions tested ethanol had no effect on HLA-
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DR expression. Benoxaprofen, ETYA, and NDGA were dissolved in 
minimal amounts of l N NaOH, immediately neutralized with 1 N 
HCl, and diluted (as was imidazole directly) in RPMI- 10% 6 FCS to 
the fin al concentrations des ired. 
TABLE I. Expression of Langerhans cell HLA -DR antigens following 
exposure of dispersed epidermal cells to IFN-a/ph.a.2 and IFN-gamma. 
DW/ T6• Lan-
Dispersed Epidermal Cell Cultures 
Dispersed epidermal cells (5 x 105) isolated from neonatal human 
foreskin as described in [7), were maintained in vitro at 37·c for 20 h 
in humidified 5% C0 2 in 2.0 ml RPMI-1640 containing 10% llFCS and 
t he indicated concentrations of either pure, E. coli recombinant DNA 
derived human IFN-alpha2, IFN-gamma, or other compounds as indi-
cated. Dispersed epidermal cells from adult facial skin were isolated 
and maintained as indicated above in 3 separate experiments. 
Detection of LC Surface Antigens HLA -DR and T6 on Dispersed 
Epidermal Cells 
Simultaneous detection of HLA-DR and T6 antigen-bearing cells 
was ach ieved under epifluorescent microscopy following sequential 
t reatment of the epidermal cells with mouse monoclonal anti-HLA-DR 
IgG, (Ortho Diagnostics, Rari tan, New J ersey) , rhodaminated goat 
antimouse IgG (Meloy Labs, Springfield, Virginia), mouse monoclonal 
anti-T1 IgG (to saturate free antimouse IgG binding sites), and flu-
oresceinated mouse monoclonal anti-T6 lgG (Ortho Diagnostics) [26). 
Epidermal cells were examined as wet mounts under epifluorescent 
microscopy with appropriate excitatory and barrier filters and the mean 
number, and SD, of DR+ / T6+ cells were calculated. 
Skin Explant Incubation In Vitro 
Four millimeter-diameter specimens of freshly excised human neo-
natal foreskin, trimmed of fat and dermis, were maintained in vitro 
under conditions identical to those described for dispersed epidermal 
cells. After 20 h in cul ture, in tact epidermal sheets were prepared from 
each specimen following incubation in 1 N NaBr at 37•c for 60 min. 
Adult facial skin prepared and mainta ined under these conditions was 
utilized in 2 separate experiments. 
Detection of HLA-DR Bearing LC in Epidermal Sheets 
Epidermal sheets were incubated with either mouse monoclonal anti-
HLA-DR IgG or anti-T6 IgG (Ortho Diagnostics) followed by incuba-
tion with fluoresceinated goat antimouse lgG (Meloy Labs), at 23 · c 
[26]. The number of fluorescing, dendritic cells in ten 400 x fields was 
counted under epifluorescent microscopy and a mean and SEM per 
mm 2 calculated. 
Statistics 
The statistical difference between means was calculated using the 
Student's one-tailed t-test with probability values less than 0.01 being 
considered significant. 
RESULTS 
E ffect of Interferons on Expression of HLA-DR Antigens by 
Dispersed Epidermal Cells 
To determine their effects on surface HLA-DR expression, 
E. coli-derived IFN-alpha2 and IFN-gamma were tested initially 
on cultured neonatal human epidermal cells. LCs constitute 2-
5 % of human epidermal cells [30] and, within the epidermis, 
may be specifically identified by t he presence of cell surface T6 
a n tigen [25]. We [26] and others [27,28] have reported t hat 
only half of T6-positive LCs also express HLA-DR antigens. 
As shown in Table I, the addition of IFN-gamma to huma n 
epidermal cell cultures increased the number of DR+ /T6+ LCs 
detected, even at the lowest concen tration (10 units/ml) tested. 
The number of DR+ cells approached, but did not exceed, the 
constant (2.40 X 104 ) total number of simultaneously detected 
T6 antigen-bearing LCs. No enhancement of DR-bearing LCs 
was detected fo llowing t he addit ion of IFN-alpha2, even at 106 
units/mi. 
Treatment Units/ml gerhans' % T6• LCs 
Cell s X w-• (SO) 
None 1.23 (0.36) 51.2 
IFN-alpha2 102 1.02 (0.27) 42.5 
10' 1.23 (0.27) 51.2 
106 1.50 (0.35) 62.5 
IFN-gamma 101 1.93 (0.25) 80.4. 
102 1. 78 (0.45) 74. 1 b 
103 2.09 (0.48) s1.o• 
10' 2.32 (0.58) 96.6. 
o Dispersed human neonatal foreskin epidermal cells (5 x 105) were 
maintained in vitro in the presence and absence of the indicated 
concentrations of IFN-alpha2 and IFN-gamrna, as described in Mate-
rials and Methods. No DR+ /T6- were observed in any of these cultures 
which contained 2.40 (0.17 SO) x 10' T6+ LCs. The data presented are 
the results of 1 experiment and are representative of 4 separate exper-
iments. 
• Significantly different (p < 0.01) from untreated control. 
TABLE II. Effect of IFN-alpha2 and IFN-gamma on expression of 
HLA -DR antigens on Langerhans cells in situ 
T1reatment11 
None 
JFN -alpha2 
IFN-gamma 
Uni ts/ml 
101 
102 
103 
IO' 
105 
101 
102 
103 
10' 
105 
HLA·DW 
Langerhans• % Control 
Cells per mm 2 (SEM) 
267.3 (25.6) 100.0 
241.5 (16.1) 90.3 
257.6 (19.3) 96.3 
265.6 (20.9) 99.3 
209.3 (14 .5) 78.3 
276.9 (22.5) 103.5 
309.1 (17.7) 115.6 
383.2 (29.0) 143.3' 
544.2 (29.0) 203.5' 
520.0 (38.6) 194.5' 
566.7 (40.3) 212.0' 
o Four millimeter-diameter specimens of freshly excised human neo-
natal foreskin, trimmed of fa t and dermis, were maintained in vitro as 
described in Materials and Methods. 
• Epidermal sheets were stained by indirect immunofluorescence for 
HLA-DR bearing cells as described in Maten:als and Methods. The 
number of fluorescing, dendritic cells in 10 fields were counted under 
epifluorescent microscopy (400X) and a mean and SEM per mm 2 
calculated. 
' Significantly different (p < 0.01) from untreated control. 
0.20 (SEM) of a ll epidermal cells in control cul tures to 2.00% 
± 0.48 after 20 h of incubation with IFN-gamma. 
Effect of Interferons on Expression of HLA-DR Antigens on 
LCs in Situ 
To further approximate in vivo conditions and to avoid 
enzymatic treatments and other physical manipulat ions re-
quired to isolate and disperse epidermal cells for culturing (7], 
superficial specimens of human foreskin were maintained in 
culture for 20 h in the absence and presence of various concen-
trations of IFN-gamma and IFN-alphaz. Following treatment 
of t he specimens with NaBr, the number of DR a nd T6 antigen -
bearing cells per mm2 in the resultant epidermal sheets was 
calculated. As shown in Table II, exposure to IFN-gamma (10 1-
105 units/ml) enhanced t he detection of DR antigen-bearing 
epidermal cells with no increases being detected fo llowing t he 
addition of identical concentrations of IFN-alpha 2• All DR-
bearing cells were dendritic, and T6 antigen-bearing LCs were 
not increased in number. The IFN 7gamma en ha ncement of DR-bearing LCs was not 
restricted to neonatal epidermal cells but a lso occurred when 
adu lt epidermal cells were studied. In 3 experiments utilizing 
a dult face s kin epidermal cell cultures, incubation with 103 
units/ml of IFN-gamma was found to double t he number of 
epidermal cells expressing HLA-DR a ntigens from 1.08% ± 
We found t his in vitro method utilizing intact skin specimens 
to be a simple and reproducible technique for studying LC 
surface a ntigens. As detailed in Table III, a series of 9 such in 
situ experiments using 20 h of foreskin exposure to 10~1 uni ts/ 
ml IFN -gamma reproducibly increased t he density of HLA-DR 
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TABLE III. IFN-gamma enhancement of Langerhans cell HLA-DR 
antigenicity in situ 
HLA-DH+ Langerhans cell s 
Experiment" per mm
2 (SEM) 
Control IFN-gamma• %Control 
1 313.9 (16.1) 529.6 (25.7) 168.7 
2 319.5 (10.0) 496.7 (16.9) 155.4 
3 294.6 (26.8) 513.5 (36.5) 174.3 
4 322.0 (1 0.4) 604 .5 (35.4) 187.7 
5 267.3 (25.6) 544 .2 (29.0) 203.5 
6 273.7 (15.0) 500.7 ( 12.1) 182.9 
7 314.0 (11.1) 567 .3 (14.5) 180.6 
8 286.6 (9.7) 518.4 (22.5) 180.8 
9 342.9 (12.7) 623.1 (17.2) 181.7 
Mean: 177.9 (4 .3) 
"Nine separate experiments were carried out in which human fore-
skin specimens were prepared, cultured, and analyzed for epidermal 
HLA-DR antigenicity as described in Materials and Methods, employ-
ing 103 units/ ml IFN-gamma. 
• Each value listed in this column is significantly different (p < 0.01) 
from its corresponding untreated control value. 
antigen-bearing LCs over control specimens by 77.9% ± 4.3 
(SEM) . Extending the duration of incubation with IFN-gamma 
to 48 h did not result in any further increases in HLA-DR+ 
LCs. 
As observed with dispersed epidermal cell cu ltures, IFN-
gamma also enhanced the expression of HLA-DR by LCs in 
situ in adult skin specimens. In 2 separate experiments using 
specimens of adult face skin, incubation with 103 units IFN-
gamma increased the number of in situ DR+ cells/mm2 by an 
average of 80% over controls. 
Inhibition of IFN-gamma Enhancement of LC HLA -DR 
Expression by Monoclonal Anti-IFN-gamma 
To be certain t hat cloned IFN-gamma itself and not some 
other E. coli-derived contaminant possibly present in our IFN-
gamma preparation was inducing HLA-DR expression, we stud-
ied IFN-gamma induced DR enhancement in t he presence of a 
monoclonal anti-IFN-gamma. The add ition of 100 units/ml 
IFN-gamma to in tact foreskin specimens significantly (p < 
0.01) increased the percentage of HLA-DR+ cells (136.1% ± 
3.5) over that present in untreated controls (100.0% ± 2.1). 
The simultaneous addition of 400 neutralizing units/ml of anti 
IFN-gamma monoclonal antibody significantly (p < 0.01) pre-
vented (102.2% ± 2.2) HLA-DR expression induced by IFN-
gamma. T he percentage of HLA-DR+ cells in specimens treated 
with this antibody a lone did not differ s ignificantly from un-
treated control specimens. The presence of a mouse monoclonal 
anti -IFN-alpha antibody did not significantly prevent IFN-
gamma induced HLA-DR expression nor did it affect the num-
ber of HLA-DR+ cells in control specimens. 
Inhibition of IFN-gamma Induced HLA-DR Expression on 
LCs by PGE2 
PGE, and PGE1 , both products of fatty acid cyclooxygenase 
action on arachidonic acid, inhibit lymphokine-induced murine 
macrophage expression of Ia antigens [18,29]. These findings 
prompted us to determine whether PGE2 could inhibit optimal 
induction by IFN-gamma of HLA-DR expression on LCs con-
tained in cu ltured foreskin specimens. As shown in Table IV, 
10- 7 M PGE2 effectively inhibited the HLA-DR expression 
induced by 103 units IFN-gamma/ml, while TXB2 had no such 
inhibitory activity. This observation suggests that IFN-gamma 
may be inducing HLA-DR expression on LCs by inhibiting the 
synthesis of PGE2. 
Enhancement of LC HLA-DR Antigenicity by Fatty Acid 
Cyclooxygenase Inhibitors 
In order to demonstrate that inhibition of PGE2 synthesis 
can result in enhanced expression of HLA-DR antigen on LCs, 
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we investigated whether compounds inhibiting PGE2 synthesis 
via inhibition of fatty acid cyclooxygenase could in the absence 
of exogenously added IFN-gamma increase HLA-DR expres-
sion. Foreskin specimens were maintained either in RPM! 
alone or in RPMI containing IFN-gamma at 103 units/ml, in 
the presence or absence of known inhibitory concentrations of 
indomethacin, a specific cyclooxygenase inhibitor [31] or be-
noxaprofen, ETYA, and NDGA, compounds which inhibit both 
the cyclooxygenase and lipoxygenase metabolism of arachi-
donic acid [32- 34] . As shown in Fig 1, a ll these inhibitors 
significantly increased the number of HLA-DR antigen-bearing 
epidermal LCs, with indomethacin, ETY A, and NDGA ap-
proaching values induced by IFN-gamma. Thus, known inhib-
TABLE IV. Effect of prostaglandin E2 and thromboxane 8 2 on IFN-
gamma induced HLA-DR expression on Langerhans cells in situ 
Treatment 
None• 
IFN-gamma 
PGE2 
IFN -Gamma + PGE2 
No ned 
IFN-gamma 
TXB2 
IFN-gamma + TXB2 
HLA-DR+ Langerhans" 
Cells % Control (SEM) 
100.0 (3.9) 
162.7 (5.1) 
102.8 (4.3) 
123.2 (5.1)' 
100.0 (5.9) 
172.1 (7.6) 
101.9 (7.8) 
157.3 {4.3) ' 
"Human foreskin specimens were prepared, cu ltured, and analyzed 
for epidermal HLA-DR antigenicity as described in Materials and 
Methods and the number of HLA-DR+ LCs expressed as a percentage 
of those present in the untreated control. 
1
' Results are the mean of 9 separate experiments employing 10a 
units/ml IFN-gamma and 10- 7 M PGE2 . 
' Significantly different (p < 0.01) from value for IFN-gamma treat-
ment alone. 
d Results are the mean of 5 separate experiments employing 103 
units/ ml IFN-gamma and w-s M TXB2. 
' Does not significantly differ (p > 0.01) from value for IFN-gamma 
treatment alone. 
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FIG 1. Effect of arachidonate cyclooxygenase inhibitors on the 
expression of Langerhans cell HLA-DR antigenicity in situ. 
Superficial foreskin specimens were prepared and maintained as 
described in Materials and Methods in the absence or presence of the 
compounds indicated. The bars represent the mean ± SEM of 16 
separate experiments for controls, 8 experiments for indomethacin 
(10-'' M), 6 experiments for benoxaprofen (10-'' M), 3 experiments for 
ETYA (10- 5 M), 4 experiments for NDGA (10- 5 M) , and 3 experiments 
for imidazole (lo-• M). Cross-hatched bars indicate the presence of 103 
units/ml IFN-gamma and open bars indicate its absence. Results are 
shown as the number of HLA-DR+ cells expressed as a percentage of 
those present in untreated controls. All t reatments significantly (p < 
0.01) increased HLA-DR+ cells over untreated controls with the excep-
tion of the addition of imidazole alone. 
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itors of PGE2 synthesis mimic the action of IFN-gamma induc-
ing HLA-DR ant igen expression on LCs, a situation having 
been prev iously reported for murine macrophages [29]. Incu-
bation in the presence of imidazole, a relatively selective inhib-
itor of thromboxane synthetase, failed to induce HLA-DR 
expression [35] . 
DISCUSSION 
We have studied the effects of cloned IFN-gamma and IFN-
alpha2 upon the expression of HLA-DR histocompatibility an-
tigens by human epidermal cells maintained in vitro as suspen-
sion cultures and as intact skin explants. The data presented 
show that cloned human IFN-gamma, but not IFN-alpha2, 
increases the number of epidermal cells expressing HLA-DR 
antigens approximately 2-fold after 20 h of exposure. HLA-DR 
was induced only on LCs as only T6-positive cells expressed 
HLA-DR antigen, and t he total number of OR-positive cells 
(constitutive + induced) never exceeded the number of T6-
positive LCs present. Whether IFN-gamma, in addition to 
inducing the presence of HLA-DR determinants on DR- /T6+ 
LCs, can also increase the degree of expression of HLA-DR on 
DR+ /T6+, as has been reported for human monocytes [20], 
cannot be determined by simple immunofluorescent micros-
copy. However, the induction of HLA-DR antigens by IFN-
gamma (and not by IFN -alphaz) on DR-/T6+ LCs is consistent 
with similar inductions reported on other macrophage and 
macrophage-like cells otherwise expressing low or undetectable 
levels of DR-antigens [15- 18,22) . Although recent reports in-
dicate that IFN-gamma may also induce HLA-DR expression 
on epidermal keratinocytes, such induction reportedly required 
4-8 days' incubation and was never observed to occur in our 
short-term (20 h) cultures [36) . 
The in tracellular mechanisms responsible for IFN-gamma 
induction of LC HLA-DR expression have also been investi-
gated and our results suggest that IFN-gamma may act by 
inhibiting the synthesis of PGE2 • This conclusion was based 
on our observations that (1) PGE2 inhibited IFN-gamma in-
duction of HLA-DR, and (2) compounds inhibiting PGEz pro-
duction via blockade of fatty acid cyclooxygenase can increase 
HLA-DR expression on LCs in the absence of IFN-gamma. 
These results are again consistent with previous results con-
cerning Ia induction in murine macrophages [18,29). The ac-
tions of IFN -gamma and fatty acid cyclooxygenase inhibitors 
were not additive, but at the concentrations tested each agent 
alone induced the numbers of HLA-DR bearing LCs to ap-
proach the tota l number of T6-positive LCs. At lower concen -
trations such additive effects, if present, may be detected. 
The question of whether IFN-gamma acts directly on LCs to 
inhibit PGE2 production or indirectly via inhibiting PGE2 
production by other epidermal cells such as keratinocytes has 
not been addressed in this study. However, preliminary results 
using T6-positive LCs isolated by panning techniques [37) 
indicate IFN-gamma acts directly on LCs to increase HLA-DR 
expression. Such a direct mechanism of action would be con-
sistent with recent reports indicating IFN-alpha and IFN-beta 
act directly on macrophages and monocytes to inhibit prosta-
glandin synthesis by blocking phospholipase activation [38, 
39). However, additional experiments are required to determine 
the exact role of arachidonate metabolites in constitutive and 
IFN-gamma induced HLA-DR expression by epidermal LCs. 
Epidermal LCs function as stimulator cells of allogeneic T-
cell activation and as antigen-presenting cells in antigen-in-
duced T-cell proliferation and in cytotoxic T-lymphocyte gen-
eration [10- 13,24) . These immune functions are genetically 
restricted, being regulated by HLA-DR, or their murine equiv-
alent, Ia, antigens. The enhancement of epidermal LC DR-
antigenicity following exposure to IFN-gamma (although not 
to IFN-alpha2 ) may imply concomitant enhancement of DR-
regu lated LC functioning, as this has been reported in the case 
of lymphokine-induced expression of Ia determinants by mu-
rine macrophage tumor cell lines [40,41) . LC accessory cell 
functions are in all likelihood active in contact hypersensitivity, 
skin graft rejection and certain types of drug hypersensit ivities. 
We are presently examining whether the induction of HLA-
DR antigens on LCs by IFN-gamma results in an increase in 
LC accessory /stimulatory cell functions. 
The authors wish to thank Ortho Diagnostic Systems Inc. of Raritan, 
New J ersey, for t he gift of ant i-0Kla*1 and anti-OKT6 monoclonal 
antibodies. 
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